Ehab Rasmy Bendas1, Mamdouh R Rezk2, Kamal A Badr3,4. 1. Clinical Pharmacy Department, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt. ehab.wasef@fue.edu.eg. 2. Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo, 11562, Egypt. 3. Department of Pharmaceutics, Faculty of Pharmacy, Deraya University, Minya, Egypt. 4. Advanced Research Center (ARC), Nasr City, Cairo, Egypt.
Abstract
BACKGROUND AND OBJECTIVES: The purpose of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence and to investigate the pharmacokinetic properties of two formulations of fixed dose combination (FDC) tablet of sofosbuvir (SOF) and ledipasvir (LED) (400/90 mg) in 36 healthy Egyptian volunteers. METHODS: The study was performed in single-dose, randomized-sequence, open-label, reference-replicated, 3-period crossover design (RTR, TRR, RRT), with a washout period of 2 weeks. A rapid and simple LC-MS/MS method was developed and validated for the simultaneous estimation of SOF and LED using eplerenone as an internal standard (IS). RESULTS: The results showed that the 90% confidence intervals (CIs) for natural log-transformed ratios of Cmax, AUClast and AUC∞ of SOF (89.95-115.31, 98.77-109.75 and 98.79-109.75) were within the RSABE acceptance limits. The 90% CIs for natural log-transformed ratios of Cmax and AUClast of LED (87.33-115.15 and 83.82-112.26) were within the FDA bioequivalence limits (80.00-125.00). In addition, the in vitro dissolution study was done and both formulations released > 85% of drug within 15 min in the proposed dissolution medium. CONCLUSIONS: In conclusion, bioequivalence between the two fixed-dose combination products was demonstrated for both active ingredients.
RCT Entities:
BACKGROUND AND OBJECTIVES: The purpose of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence and to investigate the pharmacokinetic properties of two formulations of fixed dose combination (FDC) tablet of sofosbuvir (SOF) and ledipasvir (LED) (400/90 mg) in 36 healthy Egyptian volunteers. METHODS: The study was performed in single-dose, randomized-sequence, open-label, reference-replicated, 3-period crossover design (RTR, TRR, RRT), with a washout period of 2 weeks. A rapid and simple LC-MS/MS method was developed and validated for the simultaneous estimation of SOF and LED using eplerenone as an internal standard (IS). RESULTS: The results showed that the 90% confidence intervals (CIs) for natural log-transformed ratios of Cmax, AUClast and AUC∞ of SOF (89.95-115.31, 98.77-109.75 and 98.79-109.75) were within the RSABE acceptance limits. The 90% CIs for natural log-transformed ratios of Cmax and AUClast of LED (87.33-115.15 and 83.82-112.26) were within the FDA bioequivalence limits (80.00-125.00). In addition, the in vitro dissolution study was done and both formulations released > 85% of drug within 15 min in the proposed dissolution medium. CONCLUSIONS: In conclusion, bioequivalence between the two fixed-dose combination products was demonstrated for both active ingredients.
Authors: Sam H Haidar; Barbara Davit; Mei-Ling Chen; Dale Conner; LaiMing Lee; Qian H Li; Robert Lionberger; Fairouz Makhlouf; Devvrat Patel; Donald J Schuirmann; Lawrence X Yu Journal: Pharm Res Date: 2007-09-22 Impact factor: 4.200
Authors: Sam H Haidar; Fairouz Makhlouf; Donald J Schuirmann; Terry Hyslop; Barbara Davit; Dale Conner; Lawrence X Yu Journal: AAPS J Date: 2008-08-26 Impact factor: 4.009
Authors: Mamdouh R Rezk; Ehab R Bendas; Emad B Basalious; Iman A Karim Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2016-06-07 Impact factor: 3.205
Authors: Katja Deterding; Christoph D Spinner; Eckart Schott; Tania M Welzel; Guido Gerken; Hartwig Klinker; Ulrich Spengler; Johannes Wiegand; Julian Schulze Zur Wiesch; Anita Pathil; Markus Cornberg; Andreas Umgelter; Caroline Zöllner; Stefan Zeuzem; Armin Papkalla; Kristina Weber; Svenja Hardtke; Heiko von der Leyen; Armin Koch; Dorothee von Witzendorff; Michael P Manns; Heiner Wedemeyer Journal: Lancet Infect Dis Date: 2016-10-28 Impact factor: 25.071
Authors: Clara T M M de Kanter; Joost P H Drenth; Joop E Arends; Henk W Reesink; Marc van der Valk; Robert J de Knegt; David M Burger Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 5.577